PharmiWeb.com - Global Pharma News & Resources
02-Jun-2023

Superficial Punctate Keratitis Treatment to reach US$ 9.6 Billion by 2033 | Get Insights FMI

The global superficial punctate keratitis treatment market is slated to reach a valuation of US$ 5.3 billion in 2023. According to Future Market Insights, the market is expected to grow at a 6.33% CAGR until 2033, valued at US$ 9.6 billion.

The increase in the prevalence of infectious diseases is driving the superficial punctate keratitis treatment market, where the disease becomes more extensive as soon as the temperature rises. It is also identified that such a type of disease is common in tropical regions, therefore a rise in the global temperature influences the incidence of keratitis, thereby expediting the market.

The global demand for keratitis treatment is being determined by the rise in medical spending. There also have been a few advancements that help in limiting sales growth. With considerable investments, the keratitis treatment market provides the opportunity for detection of the coronary eye disease by embracing a good perception throughout the coming years. But this disease is also spreading due to the provision of poor sanitary conditions in developing nations.

Drivers and Challenges have an Impact on Market Dynamics, which can Impact Businesses. Find more Insights in a Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-17066

The disease is transmitted as a result of poor sanitary conditions in developing nations. Although, wearing contact lenses while swimming is another aspect ramping up the contamination of the eye, thus this is also contributing to the contribution of the keratitis treatment.

Recently, intervention in surgery may also be an option for patients with refractory superficial punctate keratitis, not responding to medical treatment, and severe fungal infections. The penetration of keratoplasty is considered to be the most common surgical intervention for serious fungal keratitis and cases with perforation or impending perforation. Modern advances have added more options like targeting the drug delivery at the site of infection in the form of intrastromal injections, collagen cross-linking, and rose Bengal-aided photodynamic therapy.

North America is said to have the dominant share due to the rapid usage of modernization and contact lens, but individuals living in developing countries, specifically in remote regions are said to get more affected because of the lack of access to healthcare providers because of low revenues.

Key Takeaways from the Market Study

  • Around 3.7 billion people under the age of 50 have Superficial Keratitis.
  • The global superficial punctate keratitis treatment market grew at a CAGR of 5.56% from 2018 to 2022
  • PCR is highly sensitive, but a large variation has been observed in numerous studies between the rates of SPK detection by PCR when compared to clinical diagnosis.
  • The treatment of Superficial Punctuate keratitis usually involves medicine, including eye drops or antiviral medications taken by mouth

Expand Operations in the Future – To Get Requisite Details, Ask for a Custom Report@ https://www.futuremarketinsights.com/customization-available/rep-gb-17066

Competitive Landscape

Some of the prominent players in the global market for Nephroblastoma Therapeutics Market treatment are-

  • Dompé Farmaceutici
  • Allergan
  • Bausch Health Companies Inc.
  • CONTACARE
  • OHTO Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Neuroptika
  • Santen Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • Grand Pharma Co., Ltd.
  • Zhejiang CONBA Pharmaceutical Co., Ltd.

Some of the important developments of the key players in the market are:

  • In November 2020, Pfizer Inc. completed the transaction to spin off its Upjohn Business and combine it with Mylan N.V. to form Viatris Inc.
  • In September 2020, Bausch Health Companies Inc. agreed to acquire an option to purchase all ophthalmology assets of Allegro Ophthalmics.
  • In August 2016, Allergen plc agreed to acquire ForSight VISIONS, a privately held, clinical-stage biotechnology company focused on eye care, for a US$ 95 million upfront payment.

More Valuable Insights Available

Future Market Insights offers an unbiased analysis of the global neurotrophic keratitis treatment market, providing historical data for 2018 to 2022 and forecast statistics from 2023 to 2033.

To understand opportunities in neurotrophic keratitis treatment, the market is segmented based on treatment type by Countries (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa), by Drugs class (Amphotericin B, Griseofulvin, Voriconazole), by Route of Administration (oral, topical), and by Distribution Channel (hospital pharmacies, retail pharmacies, and online pharmacies)

To receive extensive list of important regions, ask for TOC here @ https://www.futuremarketinsights.com/toc/rep-gb-17066

Key Segments Profiled in the Superficial Punctuate Keratitis Market Treatment Report

By Drug Class:

  • Amphotericin B
  • Griseofulvin
  • Voriconazole

By Route of Administration:

  • Oral
  • Topical

By Distribution Channel:

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Have a Look at Related Research Reports in the Healthcare Domain:

Prurigo Nodularis Treatment Market Size: The global prurigo nodularis treatment market is expected to attain a valuation of US$ 693.3 million in 2023 and is projected to reach US$ 930.9 million by 2033. The market is expected to rise at a CAGR of 3% from 2023 to 2033.

Calprotectin Testing Market Share: The calprotectin testing market is capturing a valuation of US$ 201.1 billion in 2023 and is predicted to reach US$ 360.2 billion by 2033. The market is registering a CAGR of 6% during the forecast period.

Pharmaceutical Sterility Testing Market Growth: The pharmaceutical sterility testing market is anticipated to be generated global sales revenue of US$ 1,250.7 million in 2023. Demand is expected to develop at a CAGR of 11.8% to reach a valuation of US$ 3,815.6 million by 2033.

About FMI:

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Editor Details

Last Updated: 02-Jun-2023